Insurers find themselves in the position of needing to say "yes" or "no" to GLP-1 drugs as more people seek them for weight loss
Park A, Conway M
Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, et al
For a long time, obesity was not treated as a medical conditionit was seen more as a personal choice or lifestyle issue
Therefore, we have suggested that doctors [do] not need to hold this medication from patients unless they have underlying eye conditions. Novo Nordisk, the maker of Ozempic, Wegovy and Saxenda, said patient safety is a top priority and that it continuously monitor[s] the safety profile of our medicines in collaboration with the TGA and other regulators worldwide
IF is praised for benefits like improved insulin sensitivity, fat loss, and metabolic health